Breaking News, Collaborations & Alliances

Takeda, Ovid Detail Clinical Development Program

The companies plan to initiate three clinical trials to investigate the potential of TAK-935/OV935

Takeda and Ovid Therapeutics have provided an overview of their TAK-935/OV935 broad clinical development program.    The companies plan to initiate three clinical trials: in pediatric patients with Dravet syndrome and Lennox-Gastaut syndrome, in pediatric patients with CDKL5 deficiency disorder (CDD) and Duplication 15q (Dup15q) syndrome, and an extension trial for patients with developmental and epileptic encephalopathies (DEEs) who participated in a previous TAK-935/OV935 clinical stud...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters